Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews the prescription-only cream eflornithine for managing facial hirsutism in women and reports no new clinical results; the authors evaluate its potential role in treatment.

This review compiles recent findings on the pharmacokinetics, pharmacodynamics, and pharmacogenomics of Valproate, highlighting potential new uses, benefits, and risks, but reports no new clinical results.

This article provides regulatory updates, legal briefs, and industry news, reporting no new clinical findings.

In this study, the combination of topical minoxidil 5% and betamethasone valerate 0.1% achieved slightly higher depigmentation in vitiligo of hair-bearing areas but did not show significant improvement over betamethasone valerate alone.

This article discusses the importance of raising awareness about specific adverse drug reactions, methods of prevention, and the significance of reporting them to the FDA's MedWatch program, but reports no new clinical results.

This case report describes a 36-year-old female patient with panhypopituitarism, experiencing severe adrenal insufficiency and thyroid hormone deficiency, which led to electrolyte imbalance, QT interval prolongation, and ventricular tachycardia; treatment stabilized her condition, underscoring the importance of hormonal evaluation in arrhythmia assessment.

This study found that dexamethasone nanocrystals significantly increased drug penetration into skin compared to a traditional cream formulation, suggesting potential benefits for treating inflammatory skin conditions.

This study reviewed 16 notable drug repurposing patent applications from 2025, highlighting potential new uses such as guanfacine for autonomic dysfunction and disulfiram for subarachnoid hemorrhage survival, though many disclosures lack peer-reviewed studies and no patents are granted.

This clinical study found that using a cream or lotion as an additional treatment alongside standard care for atopic dermatitis significantly reduced symptoms and improved skin moisturization and barrier function within 28 days compared to standard care alone in participants with mild-to-moderate eczema.

This article discusses the impact of PROTACs technology in transforming drug discovery with its novel degradation mechanism, but it reports no new experimental findings.

This study found that androgen deprivation therapy is associated with an increased risk of acquired long-QT syndrome and Torsades de Pointes, particularly highlighting enzalutamide's greater association with sudden death compared to other therapies.

This review highlights the potential of spanlastics, a new type of drug delivery system, to enhance drug administration by offering better deformability and stability compared to other nanocarriers, potentially improving targeted drug delivery across various applications.

This review discusses various psychiatric treatments including antipsychotics, insomnia medication, and mood stabilizers, but reports no new clinical results; the authors comment on existing findings and approvals.

This article describes viDA Therapeutics Inc.'s focus on developing new drugs for age-related conditions using their proprietary granzyme-based approach but reports no clinical outcomes, primarily discussing their funding and business strategy.

In this study, researchers developed a dexpanthenol-infused nanotechnological platform within hyaluronic acid hydrogels that promoted wound healing in mice by providing a protective barrier and significantly enhancing skin regeneration, including increased fibroblast activity and tissue remodeling.

This study found that DVd therapy is at least as effective as VAD/VAd for treating multiple myeloma and causes fewer side effects and reduced hospital visits.

This study found that topical valproate has minimal potential to cause skin irritation, suggesting it can be applied safely to human skin.

In this study, GV-350 treatment over three months improved iron status and reduced the impact of Telogen Effluvium on quality of life among 20 iron-deficient women, with no adverse events reported.

This article lists the clinically important interactions and skin reactions of several drugs and substances, including THA, FK506, tamoxifen, tamsulosin, tartrazine, tea tree oil, temazepam, and temozolomide, but provides no new clinical results.

In this study, a UK expert panel discussed strategies for managing common side effects of vismodegib, a hedgehog pathway inhibitor used for advanced basal cell carcinoma, concluding that adverse events like taste disturbances and muscle cramps can be effectively managed to optimize treatment duration.

This compilation lists potential side effects, drug interactions, and trade names of various dermatological and antiretroviral medications, but it reports no original research findings.

This review discusses the potential use of Adiantum capillus-veneris extract for COVID-19 symptom management and reports no clinical findings, highlighting a need for trials to evaluate its efficacy.

This review discusses managing common and notable adverse events associated with the antibody-drug conjugate trastuzumab deruxtecan in patients with HER2-positive unresectable/metastatic breast cancer and reports no new clinical results.

This study found that 86% of patients with follicular non-Hodgkin's lymphoma were alive and nearly two-thirds remained in complete remission eight years after initial treatment with the radioimmunotherapy drug Bexxar.

This article highlights the importance of recognizing, preventing, and reporting adverse drug reactions to the FDA's MedWatch program, but does not present new research findings.

This study investigated a new formula called SV-loaded nanospanlastics for topical application to treat androgenic alopecia. It showed similar effectiveness to minoxidil lotion but with fewer adverse effects when used to enhance dermal delivery and efficacy of sodium valproate.

Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.

This article discusses the importance of increasing awareness about specific adverse drug reactions, prevention methods, and the promotion of reporting ADRs to the FDA's MEDWATCH program; it reports no new results.

In this case series, three patients with advanced non-small cell lung cancer experienced severe skin eruptions and scarring alopecia after treatment with amivantamab, highlighting the critical need for prompt recognition and management of these adverse effects to minimize treatment interruptions.